Goldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $200.00 (from $190.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

William Blair Reiterates Outperform Rating on Abbvie (ABBV)July 26, 2024 5:37 AM Abbvie (ABBV) PT Raised to $200 at BarclaysJuly 26, 2024 3:34 AM AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisJuly 26, 2024 2:00 AM Abbvie (ABBV) PT Raised to $210 at Truist SecuritiesJuly 25, 2024 4:12 PM Abbvie (ABBV) PT Raised to $210 at JPMorganJuly 25, 2024 3:56 PM Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends ExpectedJuly 25, 2024 8:30 AM AbbVie hikes full-year earnings guidance as Humira sales top estimatesJuly 25, 2024 7:56 AM AbbVie (ABBV) Misses Q2 EPS by 5c; offers guidanceJuly 25, 2024 7:50 AM Form 8-K AbbVie Inc. For: Jul 25July 25, 2024 7:42 AM AbbVie lifts 2024 profit forecast, shares hit record highJuly 25, 2024 7:39 AM AbbVie Reports Second-Quarter 2024 Financial ResultsJuly 25, 2024 7:36 AM Stocks expected to have increasing option volume: ABBV TRU HAS KDP LUV WH IBM CMG NOW LVS July 25, 2024 5:17 AM AbbVie (ABBV) call put ratio 1 call to 1 put into quarter resultsJuly 24, 2024 11:21 AM